Form 8-K PALVELLA THERAPEUTICS, For: Dec 15

Go back to Form 8-K PALVELLA THERAPEUTICS, For: Dec 15

Palvella Therapeutics (PVLA) PT Raised to $190 at Truist Securities

December 15, 2025 2:14 PM UTC

Truist Securities analyst Danielle Brill raised the price target on Palvella Therapeutics (NASDAQ: PVLA) to $190.00 (from $105.00) while maintaining a Buy rating.

The analyst comments "We incorporated risk adjusted sales for cutaneous venous malformations (CVM) into our PVLA model which raises our PT to $190 (from... More

Palvella Therapeutics (PVLA) PT Raised to $210 at Cantor Fitzgerald

December 15, 2025 10:09 AM UTC

Cantor Fitzgerald analyst Josh Schimmer raised the price target on Palvella Therapeutics (NASDAQ: PVLA) to $210.00 (from $200.00) while maintaining a Overweight rating.

... More